Prostate Cancer Treatment Regimens
Find detailed treatment options for prostate cancer, including clinical trials and anticancer agents such as docetaxel, prednisone, and sipuleucel-T.
Genitourinary Cancer
Overactive Bladder Linked to Prostate Cancer ADT
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
Clinician Opinion Somewhat Favors Use of Shared Decision-making in Older Men with Metastatic Castration-Resistant Prostate Cancer
This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.
All-Grade AE Profiles Better Measure of Quality of Life in Metastatic Castration-Naïve Prostate Cancer
A study evaluating patient vs clinician reports of adverse events reveals which measures provide a more accurate perspective on patient quality of life.
No Decrease in Pulmonary, Surgical Outcomes With Bleomycin in Good-Risk Germ Cell Cancers
Researchers investigated whether bleomycin posed concerns regarding pulmonary or operative outcomes following PC-RPLND in men treated with chemotherapy for IGCCCG good-risk germ cell cancers.
Nonopioid Pain Medications Found to Control Postop Pain, Reduce Anxiety Effectively
Researchers presented results of a project designed to reduce opioid use while effectively managing pain and anxiety in patients who had undergone surgery for urologic cancer at the 2018 ASCO Quality Care Symposium.
Metformin Use May Improve Survival Outcomes in Bladder Cancer
A review and meta-analysis evaluated the association between metformin use and bladder cancer incidence and various prognostic measures, such as PFS and OS.
Ado-trastuzumab Emtansine Effective in HER2 Amplified Non-breast, Non-gastric Cancers
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
5-ARI Use Before, After Diagnosis Significantly Reduced Bladder Cancer-Specific Death
Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.
Recruitment for 2 Trials of Investigational ADC for Urothelial Cancer Underway
Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.
Next post in Genitourinary Cancer
